Navigation Links
Cephalon Presents Positive Results for Fentora in Breakthrough Pain,,,Associated with Neuropathic Conditions

>CONTACT: Media, Stacey Beckhardt of Cephalon, Inc., +1-610-738-6198,mobile, +1-610-247-0212, ; or Catherine Collier forCephalon, Inc., +1-212-886-2214, ; or investors,Robert (Chip) Merritt of Cephalon, Inc., +1-610-738-6376, sbeckhar@cephalon.com ccollier@cooneywaters.com officecmerritt@cephalon.com

Web site: www.cephalon.com

Company News On-Call: http://www.prnewswire.com/comp/134563.html /

Ticker Symbol: (NASDAQ-NMS:CEPH)

Terms and conditions of use apply
Copyright 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... ... August 31, 2015 , ... The 2015 New ... patients and family members, medical professionals, and researchers, covering a variety of topics ... is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista is celebrating ... 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, located at 1279 ... Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more details or stop ...
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
(Date:8/31/2015)... ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! Dr. Betsy ... Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 and was ... team captain in both sports in his senior year. He was inducted into the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... makers, diagnostic services, and others—to hold down costs? , In a commentary for ... officer of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties ...
Breaking Medicine News(10 mins):Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3
... The College of Optometrists in Vision,Development (COVD) ... O.D., FCOVD, was installed as its 29th president ... Meeting held on,October 20. Dr. Fortenbacher, 53, who ... for eight years, assumes the new role and ...
... Nov. 2 Addressing more than,100 cardiologists and ... chairman and CEO, set out four critical priorities ... today at,Schering-Plough,s fourth annual Cardiovascular Summit in advance ... In his speech, Hassan emphasized the potential ...
... 2 This week in Washington,experts and activists on ... Yoweri Museveni, acting on concerns raised by a number ... the US,to give a speech on AIDS policy, sponsored ... President Bush., "Ugandans deserve respect and recognition for ...
... But most humans couldn,t maintain such a low-cal diet, ... Cutting back drastically on daily calorie intake can lead ... at Buffalo researchers. , They speculate that this kind ... age, slowing the progression to disability. , A lifelong ...
... 2 Shoot For a Cure, the 15th anniversary,celebration ... Hospital, will be held at 6 p.m. Thursday, Nov. ... This year,s celebration will honor Bloomfield resident Penny B.,Blumenstein, ... System. The evening will include an auction, dinner ...
... Nov. 2 ABR-Affinity,BioReagents, a leading global antibody manufacturer, ... Society for,Neuroscience Meeting in San Diego, California, November 3 ... past week and a half, the influx of meeting,participants ... hard hit,economy of the region. "All of the staff ...
Cached Medicine News:Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 2Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 3Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:President Museveni's Visit Protested by HIV/AIDS Experts 2Health News:Calorie-Starved Rats Live Longer: Study 2Health News:ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: